SCTB35

SCTB35 is an investigational agent whose form is not stated in the registry developed by Sinocelltech. Its molecular target is not stated in the ClinicalTrials.gov intervention record, and OnCo has not confirmed one from the sponsor's pipeline page. ClinicalTrials.gov describes the intervention as: SCTB35 will be subcutaneously administered at a dose as specified. It is the investigational product in 2 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including phase 3 studies NCT07570823 (A Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma) and NCT07562022 (A Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma), in diffuse large B-cell lymphoma and follicular lymphoma. The largest, NCT07570823, plans to enrol 101 participants with primary completion expected 2027-11. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.